Vialox
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
A synthetic pentapeptide marketed as a topical alternative to botulinum toxin, blocking acetylcholine at the neuromuscular junction to soften expression lines. The evidence is speculative, resting on in vitro receptor binding rather than independent human trials. Whether it penetrates skin well enough to reach that junction is unresolved. Not an approved drug, sold as a cosmetic ingredient, supply is unregulated research-grade material of uncertain purity.
Read Full recordStudied uses & evidence
Studied uses(5)
Reduction of expression wrinkle depth and size
SpeculativeNo published human trial exists, reduction figures come from unpublished supplier marketing data.
Decreased skin roughness
SpeculativeNo peer-reviewed instrumental study exists, roughness figures come from unpublished supplier technical literature.
Muscle relaxation via nAChR antagonism (in vitro)
SpeculativeMechanism is manufacturer-claimed; the 2025 and 2026 studies tested other targets, without directly testing nAChR binding.
Evidence limits
- Evidence Level
- Preclinical
All clinical evidence for Vialox comes from proprietary data generated by its manufacturer, Pentapharm Ltd. This includes one in vivo study on women aged 30-60 using a half-face design over 28 days, and in vitro muscle contraction assays. These results have not been independently replicated, published in a peer-reviewed dermatology journal, or subjected to rigorous external review. Multiple peer-reviewed cosmeceutical review articles (Errante et al. 2020; Pai et al. 2017; Yotova et al. 2025) acknowledge the mechanism but explicitly note the absence of independent clinical validation. The parent peptide Waglerin-1 has robust peer-reviewed pharmacological data, but whether the truncated Pentapeptide-3 retains meaningful activity after topical application through the stratum corneum remains unproven by independent research.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Lack of independent clinical validation
HighUncertain skin penetration and bioavailability
HighContact dermatitis or skin irritation
LowAllergic reaction
LowQuality varies among unregulated products sold online
ModerateThermal and pH degradation
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.